Immunization with DNA vaccine expressing herpes simplex virus type 1 gD and IL-21 protects against mouse herpes keratitis

Immunological Investigations

Volumn 40, Issue 3, 2011, Pages 265-278

  Hu, Kai ^a   He, Xiangfeng ^a   Yu, Fangliu ^a   Yuan, Xianwen ^a   Hu, Weihua ^a   Liu, Chunsheng ^a   Zhao, Fengshu ^a   Dou, Jun ^a  

^a SOUTHEAST UNIVERSITY   (China)

Author keywords

Glycoprotein D

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; GLYCOPROTEIN D; HERPES VACCINE; INTERLEUKIN 21; INTERLEUKIN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG EFFICACY; FEMALE; GENE TARGETING; GENETIC TRANSFECTION; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; IMMUNIZATION; INOCULATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; CYTOKINES; FEMALE; IMMUNITY, CELLULAR; INTERLEUKINS; KERATITIS, HERPETIC; MICE; MICE, INBRED BALB C; VACCINATION; VACCINES, DNA; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 79952370561     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2010.534219     Document Type: Article

References (33)

1. Arefian, E., Bamdad, T., Soleimanjahi, H., et al. (2009). A kinetic study of gamma interferon production in herpes simplex virus-1 DNA prime-protein boost regimen comparing to DNA or subunit vaccination. Mol. Biol. (Mosk). 43:422-428.
2. Bernstein, D. I., Cardin, R. D., Bravo, F. J., et al. (2009). Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines. Clin. Vaccine Immunol. 16:699-705.
3. Bernstein, D. I., Stanberry, L. R., Harrison, C. J., et al. (1987). Antibody response to herpes simplex virus glycoprotein D: Effects of acyclovir and relation to recurrence. J. Infect. Dis. 156:423-429. (Pubitemid 17139382)
4. Carlo, E. D., Comes, A., Orengo, A. M. (2004). IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice. J. Immunol. 172:1540-1547. (Pubitemid 38116798)
5. Donnelly, J. J., Ulmer, J. B., Shiver, J. W., et al. (1997). DNA vaccines. Annu. Rev. Immunol. 15: 617-648. (Pubitemid 27169294)
6. Dou, J., Chen, J., Chen, G., et al. (2005). Novel constructs of tuberculosis gene vaccine and its immune effect in mice. Cell Mol. Immunol. 2:88-93.
7. Dou, J., Liu, P., Wang, J., et al. (2006). Effect of hepatitis C virus core shadow protein expressed in human hepatoma cell line on human gene expression profiles. J. Gastroenterol. Hepatol. 21:1794-1800. (Pubitemid 44656999)
8. Dou, J., Wang, Y., Wang, J., et al. (2009). Antitumor efficacy induced by human ovarian cancer cells secreting IL-21 alone or combination with GM-CSF cytokines in nude mice model. Immunobiology 214:483-492.
9. Fengshu, Z., Jun, D., XiangFeng, H., et al. (2010). Enhancing therapy of melanoma efficacy via tumor cell vaccine expressing GPI-anchored IL-21 and secreting GMCSF in mouse model. Vaccine 28:2486-2852.
10. Huygen, K., (2006). DNA vaccines against mycobacterial diseases. Future Microbiol. 1:63-73.
11. Inoue, T., Inoue, Y., Nakamura, T., et al. (2000). Preventive effect of local plasmid DNA vaccine encoding gD or gD-IL-2 on herpetic keratitis. Invest. Ophthalmol. Vis. Sci. 41:4209-4215.
12. Inoue, Y., Ohashi, Y., Shimomura, Y., et al. (1990). Herpes simplex virus glycoprotein D: Protective immunity against murine herpetic keratitis. Invest. Ophthalmol. Vis. Sci. 31:411-418. (Pubitemid 20117054)
13. Ishikawa, H., Ma, Z., Barber, G. N. (2009). STING regulates intracellular DNAmediated, type I interferon-dependent innate immunity. Nature 461:788-792.
14. Jamali, A., Mahdavi, M., Hassan, Z. M., et al. (2009). A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine. Int. Immunol. 21:217-225.
15. Jun, D., Guobin, C., Jing, W., et al. (2004). Preliminary study on mouse interleukin 21 application in tumor gene therapy. Cell. Mol. Immunol. 1:388-396.
16. Jun, D., Kezhou, L., Zhi, C., et al. (1999). Effect of immunization in mice with recombinant DNA encoding the hepatitis C virus structural protein. Chin. Med. J. 112:1036-1039.
17. Jun, D., Quan, T., Fangliu, Y., et al. (2010). Investigation of immune effect based on BCG priming and Plasmid DNA expressing Ag85A and GM-CSF boosting in Balb/c mice model. Immunobiology 215:133-142.
18. Jun, D., Quan, T., Fengshu, Z., et al. (2008). Comparison of immune responses induced in mice by vaccination with DNA vaccine constructs expressing Mycobacterial antigen 85A and Interleukin- 21 and Bacillus Galmette- Guérin. Immunol. Invest. 37:113-127.
19. Knickelbein, J. E., Hendricks, R. L., Charukamnoetkanok, P. (2009). Management of herpes simplex virus stromal keratitis: An evidence-based review. Surv. Ophthalmol. 54:226-234.
20. Letvin, N. L., Walker, B. D. (2003). Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med. 9:861-866. (Pubitemid 36889927)
21. Liu, X., Broberg, E., Watanabe, D., et al. (2009). Genetic engineering of a modified herpes simplex virus 1 vaccine vector. Vaccine 27:2760-2767.
22. Mark, A., Brockman, I., David, M. K. (2008). Herpes simplex virus as a tool to define the role of complement in the immune response to peripheral infection. Vaccine 26(Suppl 8): I94-I99.
23. McGowin, C. L., Pyles, R. B.(2010) Mucosal treatments for herpes simplex virus: Insights on targeted immunoprophylaxis and therapy. Future Microbiol. 5:15-22.
24. Mosmann, T. R. (1983). Colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Meth. 65:55-63.
25. Parrish-Novak, J., Dillon, S. R., Nelson, A., et al. (2000). Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408:57-63.
26. Perng, G. C., Jones, C. (2010). Towards an understanding of the herpes simplex virus type 1 latency-reactivation cycle. Interdiscip. Perspect. Infect. Dis. 2010:1-17.
27. Fordham, V. R., Vuola, J. M. (2002). New vaccine for prevention tuberculosis. Vaccines 35:465-474.
28. Romano, M., D'Souza, S., Adnet, P. Y., et al. (2006). Priming but not boosting with plasmid DNA encoding mycolyltransferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv. Vaccine 24:3353-3364.
29. Stanberry, L. R., Spruance, S. L., Cunningham, A. L., et al. (2002). Glycoproteinadjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347:1652-1661. (Pubitemid 35340783)
30. Taylor, P. R., Paustian, C. C., Koski, G. K., et al. (2010). Maturation of dendritic cell precursors into IL12-producing DCs by J-LEAPS immunogens. Cell Immunol. 262:1-5.
31. Wakeham, J., Wang, J., Magram, J. (1998). Lack of both types 1 and cytokines, tissue inflammatory responses, and immune protection during pulmonary infection by Mycobacterium bovis bacillus Calmette - Guerin in IL-12-deficient mice. J. Immunol. 160:6101-6111. (Pubitemid 28298074)
32. Wilson, S. S., Fakioglu, E., Herold, B. C. (2009). Novel approaches in fighting herpes simplex virus infections. Expert Rev. Anti. Infect. Ther. 7:559-568.
33. Zajac, A. J., Blattman, J. N., Murali-Krishna, K., et al. (1998). Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188:2205-2213. (Pubitemid 29028493)